[1] Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21.
[2] Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy[J]. N Engl J Med, 2014, 371(24):2277-2287.
[3] Kimura Y, Miura N, Debiec H, et al. Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy[J]. Clin Exp Nephrol, 2017, 21(1):117-126.
[4] 秦华章, 乐伟波, 刘志红. 磷脂酶A2受体与特发性膜性肾病[J]. 肾脏病与透析肾移植杂志, 2015, 24(2):165-170.
[5] Sugahara G, Kamiie J, Kobayashi R, et al. Expression of phospholipase A2 receptor in primary cultured podocytes derived from dog kidneys[J]. J Vet Med Sci, 2016, 78(5):895-899.
[6] Granata F, Petraroli A, Boilard E, et al. Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M-type receptor[J]. J Immunol, 2005, 174(1):464-474.
[7] Jaulmes A, Janvier B, Andreani M, et al. Autocrine and paracrine transcriptional regulation of type ⅡA secretory phospholipase A2 gene in vascular smooth muscle cells[J]. Arterioscler Thromb Vasc Biol, 2005, 25(6):1161-1167.
[8] Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2[J]. Annu Rev Biochem, 2008, 77(2):495-520.
[9] Augert A, Payré C, de Launoit Y, et al. The M-type receptor PLA2R regulates senescence through the p53 pathway[J]. EMBO Rep, 2009, 10(3):271-277.
[10] Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy[J]. J Am Soc Nephrol, 2011, 22(6):1137-1143.
[11] 周广宇, 金玲, 于晶, 等. 成人膜性肾病患者血清抗PLA2R抗体与病情的相关性[J]. 中华肾脏病杂志, 2012, 28(2):111-114.
[12] Timmermans SA, Ayalon R, van Paassen P, et al. Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy[J]. Am J Kidney Dis, 2013, 62(6):1223-1225.
[13] Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2012, 23(10):1735-1743.
[14] Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy[J]. Kidney Int, 2013, 83(5):940-948.
[15] Guerry MJ, Vanhille P, Ronco P, et al. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy[J]. Kidney Int, 2016, 89(6):1399.
[16] 周广宇, 张文龙, 张博, 等. 老年膜性肾病患者抗M型磷脂酶A2受体抗体检测的临床意义[J]. 中华老年医学杂志, 2015, 34(2):144-146.
[17] Li X, Wei D, Zhou Z, et al. Anti-PLA2R antibodies in Chinese patients with membranous nephropathy[J]. Med Sci Monit, 2016, 22:1630-1636.
[18] Oh YJ, Yang SH, Kim DK, et al. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy[J]. PLoS One, 2013, 8(4):e62151.
[19] Akiyama S, Akiyama M, Imai E, et al. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy[J]. Clin Exp Nephrol, 2015, 19(4):653-660.
[20] Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy:a meta-analysis[J]. PLoS One, 2014, 9(8):e104936.
[21] Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase A2 receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis[J]. Nephrol Dial Transplant, 2011, 26(8):2526-2532.
[22] Dähnrich C, Komorowski L, Probst C, et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy[J]. Clin Chim Acta, 2013, 421:213-218.
[23] Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy[J]. N Engl J Med, 2011, 364(7):689-690.
[24] Segarra-Medrano A, Jatem-Escalante E, Quiles-Pérez MT, et al. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy[J]. Nefrologia, 2014, 34(3):353-359.
[25] Ong L, Silvestrini R, Chapman J, et al. Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis[J]. Pathology. 2016, 48(3):242-246.
[26] Dou Y, Zhang L, Liu D, et al. The accuracy of the anti-phospholipase A2 receptor antibody in the diagnosis of idiopathic membranous nephropathy:a comparison of different cutoff values as measured by the ELISA method[J]. Int Urol Nephrol, 2016, 48(6):845-849.
[27] Larsen CP, Messias NC, Silva FG, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies[J]. Mod Pathol, 2013, 26(5):709-715.
[28] Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy:an updated meta-analysis[J]. Sci Rep, 2015, 5:8803.
[29] 王莉君, 尚明花, 诸葛一峰, 等. 特发性膜性肾病患者肾组织PLA2R的表达及其与免疫治疗疗效关系的初步探讨[J]. 中华医学杂志, 2016, 96(1):4-8.
[30] Wei SY, Wang YX, Li JS, et al. Serum anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy[J]. Am J Nephrol, 2016, 43(2):129-140.
[31] Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cáceres C, et al. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus[J]. Nefrologia, 2014, 34(4):491-497.
[32] Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy[J]. J Am Soc Nephrol, 2011, 22(8):1543-1550.
[33] Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(10):2545-2558.
[34] Medrano AS, Escalante EJ, Cáceres CC, et al. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens[J]. Biomarkers, 2015, 20(1):77-83.
[35] Hoxha E, Harendza S, Pinnschmidt H, et al. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system[J]. PLoS One, 2014, 9(10):e110681.
[36] Timmermans SA, Abdul Hamid MA, Cohen Tervaert JW, et al. Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy[J]. Am J Nephrol, 2015, 42(1):70-77.
[37] Bech AP, Hofstra JM, Brenchley PE, et al. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2014, 9(8):1386-1392.
[38] Debiec H, Martin L, Jouanneau C, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy[J]. Am J Transplant, 2011, 11(10):2144-2152.
[39] Kattah A, Ayalon R, Beck LH Jr, et al. Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy[J]. Am J Transplant, 2015, 15(5):1349-1359.
[40] Gupta G, Fattah H, Ayalon R, et al. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation[J]. Clin Transplant, 2016, 30(4):461-469.
[41] 经子兰,任丽丽,赵昕,等.主动脉内球囊反搏辅助治疗冠心病合并慢性肾脏疾病的PCI患者临床疗效观察[J].解放军医学杂志,2015,40(4):266-270. |
